These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3551834)

  • 61. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors.
    Sirot D; Chanal C; Henquell C; Labia R; Sirot J; Cluzel R
    J Antimicrob Chemother; 1994 Jun; 33(6):1117-26. PubMed ID: 7928805
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of plasmid-encoded beta-lactamase resistance in Escherichia coli blood culture isolates.
    Huovinen S; Huovinen P; Torniainen K; Jacoby GA
    Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):651-5. PubMed ID: 3143575
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Development of gene probes and evolutionary relationships of the PSE-4 bla gene to plasmid-mediated beta-lactamases of gram-negative bacteria.
    Boissinot M; Huot A; Mercier J; Levesque RC
    Mol Cell Probes; 1989 Jun; 3(2):179-88. PubMed ID: 2788807
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
    Thomson CJ; Amyes SG
    J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Increased detection of extended spectrum beta-lactamase producing Salmonella enterica and Escherichia coli isolates from poultry.
    Dierikx C; van Essen-Zandbergen A; Veldman K; Smith H; Mevius D
    Vet Microbiol; 2010 Oct; 145(3-4):273-8. PubMed ID: 20395076
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mechanisms of hyperproduction of TEM-1 beta-lactamase by clinical isolates of Escherichia coli.
    Wu PJ; Shannon K; Phillips I
    J Antimicrob Chemother; 1995 Dec; 36(6):927-39. PubMed ID: 8821592
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Occurrence and diversity of integrons and beta-lactamase genes among ampicillin-resistant isolates from estuarine waters.
    Henriques IS; Fonseca F; Alves A; Saavedra MJ; Correia A
    Res Microbiol; 2006 Dec; 157(10):938-47. PubMed ID: 17125975
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Back mutations to the TEM-1 beta-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid.
    Thomson CJ; Amyes SG
    J Med Microbiol; 1995 Jun; 42(6):429-32. PubMed ID: 7791208
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Spread of SHV-1 beta-lactamase in Escherichia coli isolated from fecal samples in Africa.
    Shaokat S; Ouellette M; Sirot D; Joly B; Cluzel R
    Antimicrob Agents Chemother; 1987 Jun; 31(6):943-5. PubMed ID: 3304158
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae.
    Papanicolaou GA; Medeiros AA; Jacoby GA
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2200-9. PubMed ID: 1963529
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Diversity of TEM mutants in Proteus mirabilis.
    Bonnet R; De Champs C; Sirot D; Chanal C; Labia R; Sirot J
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2671-7. PubMed ID: 10543745
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An additional ionic bond suggested by molecular modelling of TEM-2 might induce a slight discrepancy between catalytic properties of TEM-1 and TEM-2 beta-lactamases.
    Chaïbi EB; Farzaneh S; Péduzzi J; Barthélémy M; Labia R
    FEMS Microbiol Lett; 1996 Oct; 143(2-3):121-5. PubMed ID: 8964456
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mutants of the TEM-1 beta-lactamase conferring resistance to ceftazidime.
    Payne DJ; Marriott MS; Amyes SG
    J Antimicrob Chemother; 1989 Aug; 24(2):103-10. PubMed ID: 2676935
    [TBL] [Abstract][Full Text] [Related]  

  • 74. High diversity of extended-spectrum beta-lactamases among clinical isolates of Enterobacteriaceae from Portugal.
    Machado E; Coque TM; Cantón R; Novais A; Sousa JC; Baquero F; Peixe L;
    J Antimicrob Chemother; 2007 Dec; 60(6):1370-4. PubMed ID: 17913717
    [TBL] [Abstract][Full Text] [Related]  

  • 75. TRC-1: emergence of a clavulanic acid-resistant TEM beta-lactamase in a clinical strain.
    Thomson CJ; Amyes SG
    FEMS Microbiol Lett; 1992 Mar; 70(2):113-7. PubMed ID: 1316862
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sequence analysis and evolutionary perspectives of ROB-1 beta-lactamase.
    Juteau JM; Levesque RC
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1354-9. PubMed ID: 2201253
    [TBL] [Abstract][Full Text] [Related]  

  • 77. OHIO-1 beta-lactamase is part of the SHV-1 family.
    Shlaes DM; Currie-McCumber C; Hull A; Behlau I; Kron M
    Antimicrob Agents Chemother; 1990 Aug; 34(8):1570-6. PubMed ID: 2121093
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Study on prevalence and molecular mechanisms of antibacterial resistance in Gram-negative pathogens of nosocomial infections in hospitals of Moscow and Perm'].
    Mudrak DE; Ikriannikova LN; Sidorenko SV; Il'ina EN
    Antibiot Khimioter; 2007; 52(7-8):10-6. PubMed ID: 18986019
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.
    Tenover FC; Raney PM; Williams PP; Rasheed JK; Biddle JW; Oliver A; Fridkin SK; Jevitt L; McGowan JE;
    J Clin Microbiol; 2003 Jul; 41(7):3142-6. PubMed ID: 12843054
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evaluation of methods for AmpC beta-lactamase in gram negative clinical isolates from tertiary care hospitals.
    Singhal S; Mathur T; Khan S; Upadhyay DJ; Chugh S; Gaind R; Rattan A
    Indian J Med Microbiol; 2005 Apr; 23(2):120-4. PubMed ID: 15928443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.